Director getting busted was the last nail in the coffin even before that quality wise things were kinda downhill.
United States Food and Drug Administration (USFDA) has issued Form 483 with 10 observations after the inspection of its unit IX, Gundlamachnoor facility
Aurobindo received Form 483 following an inspection of the company’s oral manufacturing facility in Jadcherla, India, outside of the city of Hyderabad. The report showed several quality control observations, but the company had promised to work with the FDA to get the issues resolved.(Unit 7)
Aurobindo’s active pharmaceutical ingredient (API) manufacturing facility in Hathnoora, India, with a total of 10 observations by the US regulator.
Aurobindo’s Unit XI was inspected by US FDA between July 25 and August 2, 2022. Network 18 accessed form 483 issued to Aurobindo Pharma’s Unit 11, Srikakulam
Discl: Exited around 520 range. Bought again as it fell below 450
| Subscribe To Our Free Newsletter |
